Biotinylated Human HLA-A*02:01&B2M&MAGE-A3 (KVAELVHFL) Monomer Protein
Catalog No: MAGEA3-HB004
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
Product overview
Recombinant Biotinylated Human HLA-A*02:01&B2M&MAGE-A3 (KVAELVHFL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and KVAELVHFL peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) &KVAELVHFL).
Product Details
- Molecular Aliases
- MAGE-A3
- Protein Length
- Gly25-Thr305
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 50.50 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human HLA-A*02:01&B2M&MAGE-A3 (KVAELVHFL) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human HLA-A*02:01&B2M&MAGE-A3 (KVAELVHFL) Monomer is greater than 95% as determined by SEC-HPLC.
Background
Melanoma antigen family A, 3 (MAGE-A3) is a cancer-testis antigen whose expression has been demonstrated in a wide array of malignancies including melanoma, brain, breast, lung and ovarian cancer. In addition, its ability to elicit spontaneous humoral and cellular immune responses has been shown in cancer patients.
References
- Esfandiary A, Ghafouri-Fard S. MAGE-A3: an immunogenic target used in clinical practice. Immunotherapy. 2015;7(6):683-704. doi: 10.2217/imt.15.29. Epub 2015 Jun 23. PMID: 26100270.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.